Shoulder Innovations, Inc. (NYSE:SI) Stock Has Consensus Target Price of $25.75 According to Brokerages

Shoulder Innovations, Inc. (NYSE:SI – Get Free Report) has been assigned an average rating of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $25.75.

Several research analysts recently issued reports on the stock. BTIG Research upped their price target on shares of Shoulder Innovations from $26.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Weiss Ratings reissued a “sell (d)” rating on shares of Shoulder Innovations in a report on Friday, October 30th. Piper Sandler restated an “overweight” rating and issued a $25.00 price objective (up from $19.00) on shares of Shoulder Innovations in a research report on Friday, August 7th. Finally, UBS Group raised their price objective on shares of Shoulder Innovations from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Monday, August 10th.

Check Out Our Latest Analysis on SI

Shoulder Innovations Trading Down 1.0%

Shares of SI opened at $20.10 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 8.69 and a current ratio of 10.68. The company has a market cap of $420.49 million, a price-to-earnings ratio of -12.41 and a beta of -1.51. The stock has a fifty day moving average price of $19.15 and a two-hundred day moving average price of $17.50. Shoulder Innovations has a 52-week low of $12.00 and a 52-week high of $24.59.

Shoulder Innovations (NYSE:SI – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.15. Shoulder Innovations had a negative return on equity of 25.37% and a negative net margin of 51.72%. The company had revenue of $16.19 million for the quarter. Analysts predict that Shoulder Innovations will post -1.70 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Healthcare Holding B.V. Gilde sold 1,196 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $22.60, for a total value of $27,029.60. Following the completion of the sale, the insider owned 2,185,914 shares of the company’s stock, valued at $49,401,656.40. This trade represents a 0.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Robert Ball sold 10,175 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $18.45, for a total transaction of $187,728.75. Following the completion of the transaction, the chief executive officer owned 380,824 shares of the company’s stock, valued at $7,026,202.80. This trade represents a 2.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 12,052 shares of company stock worth $230,163 over the last quarter. 29.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. bought a new stake in shares of Shoulder Innovations during the third quarter worth $2,472,000. Russell Investments Group Ltd. lifted its stake in shares of Shoulder Innovations by 2,151.8% during the third quarter. Russell Investments Group Ltd. now owns 73,025 shares of the company’s stock valued at $1,380,000 after acquiring an additional 69,782 shares during the period. Royal Bank of Canada boosted its holdings in Shoulder Innovations by 7,046.3% in the first quarter. Royal Bank of Canada now owns 53,883 shares of the company’s stock valued at $783,000 after acquiring an additional 53,129 shares during the last quarter. Marshall Wace LLP boosted its holdings in Shoulder Innovations by 29.7% in the third quarter. Marshall Wace LLP now owns 50,162 shares of the company’s stock valued at $948,000 after acquiring an additional 11,495 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in Shoulder Innovations in the second quarter valued at about $896,000.

About Shoulder Innovations

(Get Free Report)

Shoulder Innovations, Inc. is a medical technology company focused on developing and commercializing products for shoulder replacement surgery. Its offerings are designed for orthopedic surgeons treating patients with shoulder conditions that may require joint replacement. The company’s product portfolio includes shoulder implant systems such as its InSet glenoid and Catalyst reverse shoulder technologies, along with related surgical instruments. These products support different approaches to shoulder arthroplasty, including procedures that replace or reconstruct parts of the shoulder joint.

Featured Stories

Analyst Recommendations for Shoulder Innovations (NYSE:SI)

Receive News & Ratings for Shoulder Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shoulder Innovations and related companies with MarketBeat.com's FREE daily email newsletter.